Defymed develops new insulin delivery device for diabetes management

French firm Defymed has developed a new insulin delivery device ExOlin to facilitate better disease management for both type 1 and type 2 diabetes patients.

Free Report

Medical Device Industry Landscape In Asia-Pacific

GlobalData's APAC Medical Devices Industry Landscape – 2022 free study breaks down the APAC medical devices market by segment and region and includes insights on local and global competitors, pipeline product developments, clinical trials studies, and significant deals in the industry. The APAC medical device industry witnessed significant developments, launches, implementations, and adoption of new medical device technologies in the past decade, however the high cost of devices, regulatory hurdles, reimbursement pressure, and healthcare budget constraints have challenged market expansion across various territories and segments. APAC is the fastest growing regional market for medical device clinical trials, with China and Japan emerging as major clinical trial hotspots. The growth in medical device clinical trials in the APAC region is attributed to an increase in research partnerships between biopharma companies and clinical research organizations (CROs). This report also provides an in-depth analysis of the medical device market's opportunities and challenges, the influence of COVID-19 on the market, and government activities aimed to develop the APAC medical device market.

By GlobalData

By clicking the Download Free Report button, you accept the terms and conditions and acknowledge that your data will be used as described in the GlobalData privacy policy

By downloading this Report, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

ExOlin consists of a biocompatible membrane that is non-biodegradable and permeable to insulin.

The device is designed as an abdominal implant and allows delivery of insulin to a physiological site when injected through the skin, in contrast to other tools such as pens and external pumps involving subcutaneous delivery.

It is expected that the new delivery device will enable stabilisation of blood sugar levels in the long-term while allowing continuation of conventional injections methods.

Defymed CEO and founder Dr Séverine Sigrist said: “With ExOlin, Defymed shall offer diabetic patients a more physiological approach for delivering insulin. The therapeutic effectiveness of the treatment should thus be significantly improved.

"The patient should also benefit from greater stability in their blood sugar levels and therefore a better quality of life."

“The patient should also benefit from greater stability in their blood sugar levels and therefore a better quality of life.”

The firm intends to commence the clinical evaluation of ExOlin next year in eight European patients, with plans to commercialise the device in the country by the end of 2020 after obtaining CE Mark.

Defymed will later apply for an approval from the US Food and Drug Administration (FDA) and seeks to raise €10m to support the process of clinical development.

In addition to diabetes management, ExOlin has the potential to be adapted for other applications and pathologies that require a physiological method to deliver drugs or active ingredients.